AMD and Other Retinal Diseases – our new study reveals trends, R&D progress, and predicted revenues Where is the AMD and Other Retinal Diseases market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead Our 169 page report provides 50 tables and 42 figures. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AMD and Other Retinal Diseases market. See how to exploit the opportunities.
Forecasts from 2016-2026 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. • Read full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including: – Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc. – Philip G. Ralston, Jr., MacuCLEAR.
Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets: • Wet age-related macular degeneration (wAMD) • Dry AMD (dAMD) • Diabetic retinopathy (DR) • Other retinal diseases (grouped forecast).
Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.
Predictions of leading products’ sales – what’s possible for those eye drug revenues? How will individual retinal medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of five prominent brands: • Lucentis • Eylea • Avastin • Visudyne • Jetrea.
Discover how high revenues can go. See what’s happening, understanding the trends, challenges and opportunities.
Our analysis also divides the main global forecast into geographical markets.
What are the prospects in the leading regions and countries? You will discover individual revenue forecasts for 10 leading national markets from 2016-2026: • United States (US) • Japan • Germany, France, the UK, Italy and Spain (EU5 group) • Brazil, Russia, India and China (BRIC countries).
There you will find countries with the highest revenues and potential growth. You can explore the outlook for treating ocular problems, serving doctors’ and patients’ needs. Assess the opportunity and ways to help people retain eyesight. Discover what the commercial prospects are for you and your organisation.
Leading companies and the potential for market growth Our analyses forecasts the world market for retinal drugs will reach $17.38bn in 2020. It will achieve strong revenue expansion from 2016 to 2026. Our report reveals how high sales will go.
You can also see which companies hold the most potential. Examine eye drug developers, producers and marketers, including these firms: • Novartis • Roche • Regeneron • Bayer • Santen • Valeant • Allergan
Research and development – assess innovation, trends and possibilities There you can also investigate R&D, appraising technological, clinical and commercial possibilities. In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others: • Combination therapies, including neovascularisation disrupters • Angiogenesis inhibition by blocking pericyte recruitment • Anti-inflammatory mechanisms (inc. corticosteroids) • Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways) • Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.
Explore the other agents and possibilities, too, including these: • Oligonucleotides and siRNA therapy • Anti-integrin oligopeptide treatment • Complement factor inhibition and serotonin modifiers • Angiotensin receptor blockers and converting enzyme inhibitors • Biosimilars and other follow-on biologicals and next generation therapeutics • Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.
The R&D holds strength, variety and promise. See what’s possible for big pharma companies and specialists in biological drugs (biologics) and other biotechnologies.
How the AMD and Other Retinal Diseases report helps you • Revenues for retinal disease treatments to 2026 – assess the overall world drugs market’s potential and receive forecasted revenues for treating wet age-related macular degeneration (wAMD), dry AMD, diabetic retinopathy (DR) and other disorders • Products’ sales to 2026 – discover the predicted revenues of Lucentis, Eylea, Avastin, Visudyne and Jetrea, seeing how those medicines can compete and succeed • National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and growth • R&D activities – see the progress, trends and prospects in that ophthalmic research and development, finding technological, clinical and commercial possibilities • Companies, news and opinions – examine the participants, including Roche, Novartis, Bayer, Regeneron and Allergan, and receive two exclusive interviews, helping your reputation for insight and staying ahead • Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantage.
Our brand new survey, by our in-house UK-based analysts, provides knowledge to benefit your research, analyses, plans, decisions and proposals. It reveals information you will find nowhere else.
Discover predictions for rear-eye medicines, getting information to help you now With our independent analyses explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.
Having that market data means you’re less likely to fall behind in knowledge or miss a crucial opportunity. Through your choice find how you could save time and effort, also benefiting your authority, reputation and results.
Our investigation provides you with definitive data, trends, opportunities and sales predictions to 2025 for retinal pharmaceuticals. So avoid missing out – please order the report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. World AMD and Other Disease Market, 2015
2.1 What are Retinal Diseases?
2.2 Types of Retinal Diseases
2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
2.4 Nearly 200 Million People with AMD?
2.5 Over 100 Million with DR
2.6 First RVO Estimates Suggest Patient Population of 16 Million
2.7 Market to Make Rapid Pace to 2026
2.8 Eylea Became Leading drug in the Market
2.9 Regeneron the Leading Presence in the Market
2.10 Which are the Most Significant Disease Areas for the Market?
3. Retinal Disease Market Subsectors, 2015
3.1 Wet AMD Still the Main Source of Revenue in the Market
3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
3.2.1 Revenue Forecasting for Wet AMD segment, 2015-2026
3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
3.3.1 Dry AMD Segment to Emerge in the Forecast Period
3.4 DR: Coming Into Clinical Focus, with DME the Main Target
3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
3.6 Projections for All Segments, 2015-2026
4. Approved Products in the AMD and Other Retinal Diseases Market, 2015-2026
4.1 Will the Current Products Dominate the Market Through 2026?
4.2 Lucentis: Second Leading Drug in the Market
4.2.1 Positive Revenue Growth Shown in Past: 2012-2015
4.2.2 Shadow of Avastin Still Hangs Over Lucentis
4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
4.2.4 Eylea: The Bigger Threat to Lucentis?
4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
4.2.6 Improving Cost and Compliance for Lucentis
4.2.7 Lucentis Revenue Forecast 2015-2026
4.2.8 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
4.3 Eylea: Holds the Throne?
4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
4.3.3 First Wave of Eylea’s Expansion Finally Beginning to Break?
4.3.4 Eylea into DME and Other New Indications
4.3.5 Eylea Revenue Forecast 2015-2026
4.3.6 How Far Can Eylea’s Momentum Carry It?
4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
4.4.2 Judicial Review Averted in the UK by Price Adjustment
4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
4.4.4 Roche and Novartis Challenge CATT’s Headline Conclusions
4.4.5 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
4.4.6 Avastin Revenue Forecast, 2015-2026
4.4.7 Will Anything Dislodge Avastin from its Central Position?
4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
4.5.1 Visudyne Revenue Forecast, 2015-2026
4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
4.6.1 Jetrea Revenue Forecast, 2015-2026
5. Pipeline for Wet AMD Segment, 2015-2026
5.1 The Leading Pipeline Candidates
5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
5.2.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
5.2.3 Ophthotech Partners with Novartis for Fovista
5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
5.2.5 The Move toward Combination Therapies
5.3 Other Growth Factor Targets in the Pipeline
5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
Table 9.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2015
Table 9.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2015
Table 9.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2016-2026
List of Figures
Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2015-2026
Figure 8.15 Market Share (%) within BRIC Group by Country, 2015
Figure 8.16 Market Share (%) within BRIC Group by Country, 2020
Figure 8.17 Market Share (%) within BRIC Group by Country, 2026
Abbott
Acucela
Alcon
Aldexa
Alimera Sciences
Alkeus Pharmaceuticals
Allegro
Allergan
Allergan and Molecular Partners
Ampio Pharmaceuticals
Association for Research in Vision and Ophthalmology
Avalanche Biotechnologies
Bayer Healthcare
Biotime
Biovail Corporation
Bristol-Myers Squibb
Casey Eye Institute
Chengdu Kanghong Biotech
Colby Pharmaceutical
Columbia University
CoMentis
Eli Lilly
EyeGate Pharmaceuticals
Eyetech
FDA
ForSight Vision4
Genentech
Germany’s Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
GlaxoSmithKline (GSK)
iCo Therapeutics
Icon Bioscience
International Diabetes Federation
Italian Competition Authority (ICA)
Japanese Ministry of Health, Labour and Welfare
Lpath, Inc.
MacuCLEAR
Mesoblast
MSD
Neuron Systems Inc.
Neurotech
NHS
NICE
Novartis
Novo Nordisk
Ocata Therapeutics
OHR Pharmaceutical
Ophthotec Corporation
Ora Bio
Oregon Health and Science University
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
PanOptica
Pfizer
QLT
Regeneron
ReVision Therapeutics
Roche
Santen Pharmaceutical
Sirion Therapeutics
StemCells
Stemedica Cell Technologies
ThromboGenics
Tyrogenex
UCB
UK’s General Medical Council
University College London (UCL)
US National Eye Institute
Valeant Pharmaceuticals
Varinel
VisionCare Ophthalmic Technologies
Vitreoretinal Technologies
WHO
Xcovery Group
Xcovery Vision
Download sample pages
Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
